BIVI — BIOVIE INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1580149 ·
Last close
$2.14
Market Cap
$18.09M
52W High
$3.79
52W Low
$0.82
ADV30
9,327,512
Next earnings
2026-08-24
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -5,385,377 | -5,270,299 | 17,514,621 | 13,098,976 | 1,907,029 |
| Dec 2025 | 0 | — | -6,262,305 | -6,069,475 | 22,503,293 | 20,540,585 | 3,238,259 |
| Sep 2025 | 0 | — | -5,284,595 | -5,087,557 | 26,820,098 | 24,978,302 | 1,899,094 |
| Jun 2025 | 0 | — | -3,663,085 | -3,489,141 | 21,562,199 | 17,544,547 | 2,550,214 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-20,510,667
Investing CF
$0
Financing CF
$10,457,629
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.96
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-368,615,121
Inventory
—
Receivables
$2,173,684
ST Investments
—
EBIT TTM
$-19,897,551
Pretax Income TTM
$-19,916,472
Interest Exp TTM
$18,921
Analysts
2
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Jun 2025 | 0 | -18,066,200 | -17,542,120 | 21,562,199 | 2,550,214 | — | -19,025,205 |
| Jun 2024 | 0 | -32,179,585 | -32,120,533 | 25,208,345 | 9,702,130 | — | -27,945,024 |
| Jun 2023 | 0 | -45,080,448 | -50,255,815 | 35,104,730 | 19,764,444 | — | -40,252,881 |
| Jun 2022 | 0 | -27,252,977 | -26,084,468 | 20,114,594 | 16,443,659 | — | -18,990,850 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.57
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PTN | PALATIN TECHNOLOGIES INC | $18.08M | $10.16 | — |
| SCNX | Scienture Holdings, Inc. | $17.76M | $0.43 | — |
| TPST | Tempest Therapeutics, Inc. | $17.58M | $1.10 | — |
| LEXX | Lexaria Bioscience Corp. | $17.42M | $10.54 | — |
| CALC | CalciMedica, Inc. | $17.10M | $0.56 | — |
News headlines (Yahoo Finance, 1h cache)
First Phosphate and BioVie Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV
2026-08-14 13:00 · Yahoo
BioVie stock sinks on Phase IIb Parkinson’s trial data
2026-08-07 11:05 · Yahoo
BioVie reports positive Phase 2 results for Parkinson's candidate bezisterim
2026-08-06 13:03 · Yahoo
BioVie Announces Topline Results of Phase 2 SUNRISE-PD Trial of Bezisterim in Early Parkinson’s Disease
2026-08-06 11:30 · Yahoo
BioVie reports positive phase 2 Parkinson's results, eyes pivotal Phase 3 trial
2026-08-05 16:18 · Yahoo
Foremost Clean Energy and BioVie Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
2026-05-29 13:00 · Yahoo
Join BioVie’s Exclusive Live Investor Webinar and Q and A Session on June 2
2026-05-27 12:00 · Yahoo
BioVie completes enrollment in Long COVID trial as need for treatments grows
2026-05-26 17:34 · Yahoo
BioVie Announces Full Enrollment of the ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
2026-05-26 12:00 · Yahoo
BioVie completes final patient visit in Parkinson's drug trial
2026-05-19 12:31 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.